Novel composite drug delivery system as a novel radio sensitizer for the local treatment of cervical carcinoma

Figures & data

Table 1. TGDrad in cervical cancer after diverse treatment groups plus different irradiation dose.

Groups	0 Gy	5 Gy	10 Gy	15 Gy	20 Gy
RT	0	6.7	12.7	18.7	24.7
PECE + RT	0	6.7	12	17.3	22.7
PTX + DDP(IT) + RT	4.7	6	12	19.9	26
PTX + DDP(IP) + RT	1.3	7.4	12	19.4	24.7
PDMP + RT	8	6.7	18	24	36.7

TGDrad: TGDrad = (TGD in each treatment group plus irradiation) – (TGD in each treatment groups without irradiation); PTX: paclitaxel; DDP: cisplatin; PDMP: mixing MPEG-PCL/PTX micelles with DDP-loaded PECE hydrogel; IP: intraperitoneal injection; IT: intra-tumor injection.

Figure 1. Dose–response curves based on TGD and TGDrad. (A) Dose–response curves based on TGD; (B) Dose–response curves based on TGDrad; TGDrad, TGDrad = (TGD per treatment group plus irradiation) – (TGD per treatment group without irradiation); PTX: paclitaxel; DDP: cisplatin; PDMP: mixing mPEG-PCL/PTX micelles with DDP-loaded PECE hydrogels; IP: intraperitoneal injection; IT: intratumoral injection.

Figure 2. Treatment with PDMP + RT inhibited tumor growth in a subcutaneous HeLa model. (A) Suppression of tumor growth after PDMP + RT treatment in mice; (B) mouse survival curves per group; PTX: paclitaxel; DDP: cisplatin; PDMP: mixing mPEG-PCL/PTX micelles with DDP-loaded PECE hydrogels; IP: intraperitoneal injection; IT: intratumoral injection.

Table 2. Tumor growth delay (in days) in cervical cancer after diverse treatment groups plus 12 Gy irradiation.

Groups	T4v0 (days)	TGD (days)
RT	26.2	14
PECE + RT	24	13.8
PTX + DDP(IP)+RT	26.6	14.4
PTX + DDP(IT)+RT	31.4	19.2
PDMP + RT	39.8	27.6

T4v0: number of days needed for tumor growth to reach four times the original volume; TGD: tumor growth delay, which in days was defined as the difference between T4V0 of treated tumors compared with untreated tumors; PTX: paclitaxel; DDP: cisplatin; PDMP: mixing MPEG-PCL/PTX micelles with DDP-loaded PECE hydrogel; IP: intraperitoneal injection; IT: intra-tumor injection.

Figure 3. Immunohistochemical analysis of γ-H2AX, CD133, and CD31 in a mouse xenograft model. PTX: paclitaxel; DDP: cisplatin; PDMP: mixing mPEG-PCL/PTX micelles with DDP-loaded PECE hydrogels; IP: intraperitoneal injection; IT: intratumoral injection.

Figure 4. Quantitative analysis of γ-H2AX, CD133, and CD31 and the expression of ATM in xenografts from mice in various treatment groups. (A) quantitative analysis of γ-H2AX in mouse xenografts in various treatment groups; (B) quantitative analysis of CD133 in mouse xenografts in various treatment groups; (C) quantitative analysis of CD31 in mouse xenografts in various treatment groups; (D) expression levels of ATM in mouse xenografts in treatment various groups; PTX: paclitaxel; DDP: cisplatin; PDMP: mixing mPEG-PCL/PTX micelles with DDP-loaded PECE hydrogels; IP: intraperitoneal injection; IT: intratumoral injection.

Figure 5. Flow cytometry analysis of tumor tissue from mice that received different treatments. (A) quantitative analysis of the percentage of cells in G1, S, G2/M phase in mouse xenografts in various treatment groups; (B) quantitative analysis of the percentage of apoptosis in mouse xenografts in various treatment groups; (C) quantitative analysis of the percentage of ALPH1 in xenografts from mice in various groups; PTX: paclitaxel; DDP: cisplatin; PDMP: mixing mPEG-PCL/PTX micelles with DDP-loaded PECE hydrogels; IP: intraperitoneal injection; IT: intratumoral injection.